PARAMOUNT: Dual-action agent shows promise in preserved-EF heart failure TheHeart.Org In a randomized comparison of the angiotensin-receptor/neprilysin inhibitor (ARNI) LCZ696 (Novartis) vs the angiotensin-receptor blocker (ARB) valsartan, levels of a heart-failure severity biomarker dropped significantly in HF-PEF patients who received ... |
